Trial Profile
Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Pharmacogenomic; Therapeutic Use
- 05 May 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 05 May 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Dec 2009 Planned end date changed from 1 Jan 2007 to 1 Jun 2012 as reported by ClinicalTrials.gov. (NCT00088907)